Navigation Links
The Female Health Company to Expand Manufacturing Capacity for FC2 Female Condom By 150%
Date:3/12/2009

CHICAGO, March 12 /PRNewswire-FirstCall/ -- The Female Health Company (NYSE Alternext: FHC) - today announced plans to install six more production lines for its FC2 Female Condom(TM), increasing its annualized FC2 production capacity in Malaysia from 30 million units to approximately 75-80 million units.

Currently, The Female Health Company is manufacturing its second-generation product, FC2, on four production lines in Malaysia. The Company, in conjunction with its Indian partner, HLL Lifecare Limited, currently produces FC2 on a fifth production line located in Kochi, India.

Mike Pope, V.P., U.K. and Malaysian operations indicated: "The Malaysian production expansion will bring the total FC2 female condom manufacturing capacity to an annualized rate of approximately 85 million units by early in the fourth quarter of calendar year 2009."

"Based on growing demand for the female condom reported by our major public sector customers that are involved in the global battle against the HIV/AIDS pandemic and the recent approval of FC2 by the U.S. Food and Drug Administration, we have elected to increase FC2 production capacity as noted," stated O.B. Parrish, Chief Executive Officer of The Female Health Company. "The demand for the female condom has been increasing rapidly with unit growth of 34% for FY 2008."

The approval by FDA permits sale of FC2 in the United States and purchases by the United States Agency for International Development for distribution in HIV/AIDS prevention programs throughout the world.

The Company is very pleased that the lower cost FC2 will now increase access by women to the Female Condom on a global basis

About The Female Health Company

The Female Health Company, based in Chicago, Illinois, manufactures and markets the FC Female Condom(R) (FC1) and the FC2 Female Condom(TM) (FC2), which are primarily distributed by public health organizations and donor groups in over 90 developing countries around the world. Globally, the Female Condoms are available in various programs in 116 countries. The Company owns certain worldwide rights to the FC1, including patents that have been issued in the United States, United Kingdom, Japan, France, Italy, Germany, Spain, the European Patent Convention, the People's Republic of China, Canada, South Korea and Australia. FC1 and FC2 are the only available FDA-approved products controlled by a woman that offer dual protection against sexually transmitted diseases, including HIV/AIDS, and unintended pregnancy.

"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995. -

The statements in this release which are not historical fact are "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this release include expectations regarding the cost of and demand for FC2. These statements are based upon the Company's current plan and strategies, and reflect the Company's current assessment of the risks and uncertainties related to its business, and are made as of the date of this release. The Company assumes no obligation to update any forward-looking statements contained in this release as a result of new information or future events, developments or circumstances. Such forward-looking statements are inherently subject to known and unknown risks and uncertainties. The Company's actual results and future developments could differ materially from the results or developments expressed in, or implied by, these forward-looking statements. Factors that may cause actual results to differ materially from those contemplated by such forward-looking statements include, but are not limited to, the following: product demand and market acceptance; competition in the Company's markets and the risk of new competitors and new competitive product introductions; the Company's reliance on its international partners in the consumer sector and on the level of spending on the female condom by country governments, global donors and other public health organizations in the global public sector; the economic and business environment and the impact of government pressures; risks involved in doing business on an international level, including currency risks, regulatory requirements, political risks, export restrictions and other trade barriers; the Company's production capacity; efficiency and supply constraints; and other risks detailed in the Company's press releases, shareholder communication and Securities and Exchange Commission filings, including the Company's Form 10-K for the fiscal year ended September 30, 2008. Actual events affecting the Company and the impact of such events on the Company's operations may vary from those currently anticipated.

For more information about the Female Health Company visit the Company's website at http://www.femalehealth.com and http://www.femalecondom.org . If you would like to be added to the Company's e-mail alert list, please send an e-mail to FHCInvestor@femalehealthcompany.com .


'/>"/>
SOURCE The Female Health Company
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Females avoid incest by causing male relatives to leave home
2. Gene Studies of Male-Female Differences Often Flawed
3. Struggling male readers respond better to female teachers
4. More sick leave given to men by male GPs compared with female counterparts
5. Researchers discover correlation between GERD and obesity in females
6. Most patients who have male-to-female sex-change surgery are happy, despite complications
7. Galderma Associates Itself to Cartiers Womens Initiative Awards to Recognize Female Entrepreneurs From Around the Globe
8. Do Not Take the Pill! Dr. Prudence Hall Tells her Teen and Female Patients
9. Female Blood Donor Concern May Be Unfounded
10. Some Female Athletes Risking Weaker Bones
11. The Female Health Company Schedules Fiscal Year End Conference Call for Monday, November 26, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Michigan (PRWEB) , ... June 24, 2016 , ... Those ... deal with these feelings, many turn to unhealthy avenues, such as drug or alcohol ... of Marne, Michigan, has released tools for healthy coping following a traumatic event. , ...
(Date:6/24/2016)... ... ... in a crisis. Her son James, eight, was out of control. Prone to extreme mood ... something upset him, he couldn’t control his emotions,” remembers Marcy. “If there was a ... children and say he was going to kill them. If we were driving on ...
(Date:6/24/2016)... ... 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced that 20 ... by their peers for this recognition are considered among the top 2 percent of ... honors as members of this year’s Legal Elite Hall of Fame: Miami Shareholders ...
(Date:6/24/2016)... ... , ... Comfort Keepers® of San Diego, CA is excited to announce they ... to drive cancer patients to and from their cancer treatments. Comfort Keepers provides ... life and ongoing independence. Getting to and from medical treatments is one of ...
(Date:6/24/2016)... , ... June 24, 2016 , ... People across the ... Genome magazine’s Code Talker Award, an essay contest in which patients and their families ... to be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 2016 Research and Markets has announced ... Diagnostic Tests" report to their offering. ... The World Market for Companion Diagnostics covers ... Market analysis in the report includes the following: ... Diagnostic Kits) by Region (N. America, EU, ROW), 2015-2020 ...
(Date:6/23/2016)... 23, 2016  MedSource announced today that it ... software solution of choice.  This latest decision demonstrates ... to their clients by offering a state-of-the-art electronic ... establishes nowEDC as the EDC platform of choice ... clients.  "nowEDC has long been a preferred EDC ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... BRAHMS PCT (procalcitonin) assay as a dedicated testing solution ... this clearance, Roche is the first IVD company in ... sepsis risk assessment and management. PCT is ... levels in blood can aid clinicians in assessing the ...
Breaking Medicine Technology: